<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Molekulyarnaya Meditsina (Molecular medicine)</journal-id><journal-title-group><journal-title xml:lang="en">Molekulyarnaya Meditsina (Molecular medicine)</journal-title><trans-title-group xml:lang="ru"><trans-title>Молекулярная медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1728-2918</issn><issn publication-format="electronic">2499-9490</issn><publisher><publisher-name xml:lang="en">Russkiy Vrach Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">113811</article-id><article-id pub-id-type="doi">10.29296/24999490-2022-05-06</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association of polymorphic variants of non-allelic genes ADIPOQ, MTHFR, PON1, KCNJ11, TCF7L2, ITLN1 and PPARG with clinical and laboratory parameters among obese patients from Kyrgyz republic</article-title><trans-title-group xml:lang="ru"><trans-title>Ассоциация полиморфных вариантов неаллельных генов ADIPOQ, MTHFR, PON1, KCNJ11, TCF7L2, ITLN1 и PPARG с клинико-лабораторными показателями среди пациентов с ожирением в Кыргызской республике</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Isakova</surname><given-names>Jainagul Tolonovna</given-names></name><name xml:lang="ru"><surname>Исакова</surname><given-names>Жайнагуль Толоновна</given-names></name></name-alternatives><bio xml:lang="en"><p>Director; Doctor of Medical Sciences, Professor.</p></bio><bio xml:lang="ru"><p>директор; Доктор медицинских наук, профессор</p></bio><email>jainagul@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kipen</surname><given-names>Viachaslau Nikolaevich</given-names></name><name xml:lang="ru"><surname>Кипень</surname><given-names>Вячеслав Николаевич</given-names></name></name-alternatives><bio xml:lang="en"><p>Leading Researcher of the Laboratory of Genetic and Cellular Engineering</p></bio><bio xml:lang="ru"><p>ведущий научный сотрудник лаборатории генетической и клеточной инженерии; Кандидат биологических наук.</p></bio><email>v.kipen@igc.cy</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aitbaev</surname><given-names>Kubanich Avenovich</given-names></name><name xml:lang="ru"><surname>Айтбаев</surname><given-names>Кубаныч Авенович</given-names></name></name-alternatives><bio xml:lang="en"><p>head lab Immunology; Doctor of Medical Sciences, professor.</p></bio><bio xml:lang="ru"><p>зав. лаб. иммунологии; Доктор медицинских наук, профессор.</p></bio><email>kaitbaev@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mukeeva</surname><given-names>Sezim Baktibekovna</given-names></name><name xml:lang="ru"><surname>Мукеева</surname><given-names>Сезим Бактыбековна</given-names></name></name-alternatives><bio xml:lang="en"><p>Junior Researcher, Laboratory of Molecular Diagnostics</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории молекулярной диагностики</p></bio><email>sez.im.mukeeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Akynbek Kyzy Samara</surname><given-names>-</given-names></name><name xml:lang="ru"><surname>Акынбек Кызы Самара</surname><given-names>-</given-names></name></name-alternatives><bio xml:lang="en"><p>Junior Researcher, Laboratory of Molecular Diagnostics</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории молекулярной диагностики</p></bio><email>s.akynbekova95@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mirrakhimov</surname><given-names>Erkin Mirsaidovich</given-names></name><name xml:lang="ru"><surname>Миррахимов</surname><given-names>Эркин Мирсаидович</given-names></name></name-alternatives><bio xml:lang="en"><p>Professor, Department of General Therapy; Doctor of Medical Sciences</p></bio><bio xml:lang="ru"><p>профессор отделения общей терапии</p></bio><email>erkmirr@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Molecular Biology and Medicine</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт молекулярной биологии и медицины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Genetics and Cytology of The National Academy of Sciences of Belarus</institution></aff><aff><institution xml:lang="ru">Государственное научное учреждение Институт генетики и цитологии Национальная академия наук Беларуси</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Center of Cardiology and Internal Medicine</institution></aff><aff><institution xml:lang="ru">Национальный Центр кардиологии и терапии им. акад. М. Миррахимова при МЗ КР</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2022</year></pub-date><volume>20</volume><issue>5</issue><issue-title xml:lang="en">VOL 20, NO5 (2022)</issue-title><issue-title xml:lang="ru">ТОМ 20, №5 (2022)</issue-title><fpage>42</fpage><lpage>52</lpage><history><date date-type="received" iso-8601-date="2022-11-18"><day>18</day><month>11</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Russkiy Vrach Publishing House</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ИД "Русский врач"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Russkiy Vrach Publishing House</copyright-holder><copyright-holder xml:lang="ru">ИД "Русский врач"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-05-15"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1728-2918/article/view/113811">https://journals.eco-vector.com/1728-2918/article/view/113811</self-uri><abstract xml:lang="en"><p>Introduction. In Kyrgyzstan about 60% of the adult population suffers from lipid metabolism disorders of varying degrees. Early identification of persons at increased risk of developing obesity is of great importance, which can be achieved through the study of molecular genetic mechanisms and the identification of genetic predictors of t of disease development. Aims. to quantify the association of g.15661G&gt;T (ADIPOQgene), p.A222V (MTHFR gene), p.Q192R (PON1 gene), p.K23E (KCNJ11 gene), g.53341C&gt;T (TCF7L2 gene), p.V109D (ITLN1 gene) and p.P12A (PPARG gene) polymorphic markers with clinical signs and blood indicators in obese subjects of Kyrgyz ethnicity. Material and methods. 130 patients with obesity (65 men and 65 women) along with 115 controls, including 62 men and 53 women were included. We used clinical, ancillary, biochemical and molecular tests in all subjects. PCR with restriction fragments was used to genotype polymorphic variants of interest. Statistical analysis was conducted in Microsoft Excel (Microsoft Corporation, USA) and SPSS v.20.0 (IBM, USA). Results. In patients with RR polymorphic variant of p.Q192R (PON1), BMI was on average 1.19 kg/m2 greater compared to those with QQ/QR alternative genotypes. T allele (CT/TT genotypes) of g.53341C&gt;T (TCF7L2) genotype in obese patients was associated with 1.45 mmol/l higher fasting blood glucose; 0.49 mmol/l total cholesterol and 2.19 units of НОМА compared to subjects with СС genotype. We also found statistically significant correlations of L-alaninaminopeptidase (LAP) with p.K23E (KCNJ11) and p.P12A (PPARG) polymorphisms. Patients carrying KK genotype of p.K23E (KCNJ11) polymorphism, which is associated with higher risk of obesity in Kyrgyz (OR 2.36 (95% CI 1.11-5.03), p=0.031), LAP was 9.03 μIU/ml lower when compared to those with EE/EK genotype. Obese patients with AA genotype of p.P12A (PPARG) showed 20.1 μIU/ml higher LAP compared to PP/AP genotypes. Conclusions. Polymorphisms p.Q192R (PON1), g.53341C&gt; T(TCF7L2), p.K23E (KCNJ11) and p.P12A (PPARG) are associated with clinical and biochemical indicators of obesity among patients of Kyrgyz nationality.</p></abstract><trans-abstract xml:lang="ru"><p>Введение. В Кыргызстане нарушениями жирового обмена различной степени страдают около 60% взрослого населения. Важное значение имеет раннее выявление лиц повышенного риска развития ожирения, которое может быть достигнуто на основе исследования молекулярно-генетических механизмов и идентификации генетических предикторов развития заболевания. Цель. Оценить взаимосвязь полиморфных вариантов g.15661G&gt;T (ген ADIPOQ), p.A222V (ген MTHFR), p.Q192R (ген PON1), p.K23E (ген KCNJ11), g.53341C&gt;T (ген TCF7L2), p.V109D (ген ITLN1) и p.P12A (ген PPARG) с клинико-лабораторными показателями среди лиц кыргызской национальности с ожирением. Материал и методы. Обследованы 130 пациентов с ожирением и 115 человек популяционного контроля. У всех обследуемых проведены клинико-инструментальные, биохимические и молекулярно-генетические исследования. Генотипирование по анализируемым полиморфным вариантам осуществлялось методом полимеразной цепной реакции (ПЦР) с определением длин рестрикционных фрагментов (ПДРФ). Статистический анализ выполнялся с использованием программы Microsoft Excel (Microsoft Corporation, США) и SPSS v.20.0 (IBM, США). Результаты. Выявлена ассоциация для полиморфизма p.Q192R (PON1) с показателем ИМТ - у пациентов с генотипом RR значение ИМТ оказалось выше в среднем на 1,19 кг/м2, чем у пациентов с альтернативными генотипами QQ/QR. Наличие аллеля T(генотипы CT/TT) по полиморфизму g.53341C&gt;T(TCF7L2) среди пациентов с ожирением было связано с повышенными значениями уровней глюкозы в крови натощак (на 1,45ммоль/л), ОХС (на 0,49 ммоль/л) и НОМА (на 2,19 условных ед.) в сравнении с пациентами с генотипом СС. Также нами показаны статистически достоверные ассоциации уровня L-аланинаминопептидазы (LAP) с полиморфизмами p.K23E (KCNJ11) и p.P12A (PPARG). У пациентов-носителей генотипа KK по полиморфизму p.K23E (KCNJ11), который ассоциирован с повышенной вероятностью развития ожирения среди лиц кыргызской национальности (ОШ=2,36; 95% ДИ - 1,11-5,03; p=0,031), уровень LAP был на 9,03 МкЕд/мл ниже в сравнении с пациентами с генотипами EE/EK. У пациентов с ожирением и генотипом AA по полиморфизму p.P12A (PPARG) уровень LAP оказался на 20,1 МкЕд/мл выше, чем среди пациентов с генотипами PP/AP. Заключение. Полиморфизмы p.Q192R (PON1), g.53341C&gt;T (TCF7L2), p.K23E (KCNJ11) и p.P12A (PPARG) ассоциированы с клинико-биохимическими показателями ожирения среди пациентов кыргызской национальности.</p></trans-abstract><kwd-group xml:lang="en"><kwd>MTHFR</kwd><kwd>PON1</kwd><kwd>KCNJ11</kwd><kwd>TCF7L2</kwd><kwd>ITLN1</kwd><kwd>PPARG</kwd><kwd>obesity</kwd><kwd>gene</kwd><kwd>association</kwd><kwd>ADIPOQ</kwd><kwd>MTHFR</kwd><kwd>PON1</kwd><kwd>KCNJ11</kwd><kwd>TCF7L2</kwd><kwd>ITLN1</kwd><kwd>PPARG</kwd><kwd>Kyrgyz population</kwd><kwd>clinical and laboratory data</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>ген</kwd><kwd>ассоциация ADIPOQ</kwd><kwd>кыргызская популяция</kwd><kwd>клинико-лабораторные показатели</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Schutz D.D., Busetto L., Dicker D., Farpour-Lambert N., Pryke R., Toplak H., Widmer D., Yumuk V., Schutz Y. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019; 12 (1): 40-66. https://doi.org/10.1159/000496183</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Султаналиева Р.Б., Князева В.Г., Распространенность сахарного диабета 2 типа и его основные факторы риска среди городских и сельских жителей Кыргызстана. Вестник КРСУ 2014; Т. 14(4): 150-153.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zayani N., Omezzine A., Boumaiza I., Achour O., Rebhi L., Rejeb J., Rejeb N.B., Abdelaziz A.B., Bouslama A. Association of ADIPOQ, leptin, LEPR, and resistin polymorphisms with obesity parameters in Hammam Sousse Sahloul Heart Study. J. Clin. Lab. Anal. 2017; 31: e22148. https://doi.org/10.1002/jcla.22148.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Isakova J., Talaibekova E., Vinnikov D., Aldasheva N., Mirrakhimov E., Aldashev A. The association of Val109Asp polymorphic marker of intelectin 1 gene with abdominal obesity in Kyrgyz population. BMC Endocrine Disorders. 2018; 18: 15. https://doi.org/10.1186/s12902-018-0242-6.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lewis S., Lawlor D.A., Nordestgaard B.G., Tybjaerg-Hansen A., Ebrahim S., Zacho J., Ness A., Leary S., Smith G.D. The methylenetetrahydrofolate reductase C677T genotype and the risk of obesity in three large population-based cohorts. Eur J Endocrinol. 2008; 159 (1): 35-40. DOI: https://doi.org/10.1530/EJE-08-0056</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Schwanstecher C., Meyer U., Schwanstecher M. K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes. 2002; 51 (3): 875-9. https://doi.org/10.2337/diabetes.51.3.875.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cauchi S., Nead K.T., Choquet H., Horber F., Potoczna N., Balkau B., Marre M., Charpentier G., Froguel P., Meyre D. The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. BMC Med Genet. 2008; 9: 45. https://doi.org/10.1186/1471-2350-9-45.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Pan H.Y, Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010; 88 (1): 29-33. DOI: 10.1016/j.diabres.2010.01.013.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Jama. 2008; 299: 1265-76. https://doi.org/10.1001/jama.299.11.1265</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Koncsos P., Seres I., Harangi M., Illyes I., Jozsa L., Gönczi F., Bajnok L., Paragh G. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res. 2010; 67: 309-13. https://doi.org/10.1203/PDR.0b013e3181c9fb66</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Li H.L., Liu D.P., Liang C.C. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003; 81: 766-779. https://doi.org/10.1007/s00109-003-0481-4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Keaney J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., Massaro J.M., Sutherland P., Vita J.A., Benjamin E.J., Study F. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003; 23: 434-9. https://doi.org/10.1161/01.ATV.0000058402.34138.11</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Bajnok L., Csongradi E., Seres I., Varga Z., Jeges S., Peti A., Karanyi Z., Juhasz A., Mezosi E., Nagy E.V., Paragh G. Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis. 2008; 197: 363-7. https://doi.org/10.1016/j.atherosclerosis.2007.06.001</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ferretti G., Bacchetti T., Moroni C., Savino S., Liuzzi A., Balzola F., Bicchiega V. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J. Clin. Endocrinol Metab. 2005; 90: 1728-33. https://doi.org/10.1210/jc.2004-0486</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sunil K.K., Meher L.K., Kota S.K., Jammula S., Krishna S.V.S., Modi K.D. Implications of serum paraoxonase activity in obesity diabetes mellitus, and dyslipidemia. Indian J. Endocrinol Metab. 2013; 17 (3): 402-12. DOI: 10.4103/2230-8210.111618</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Helgason A., Palsson S., Thorleifsson G. et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet. 2007; 39 (2): 218-25. https://doi.org/10.1038/ng1960</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Chimienti F., Devergnas S., Pattou F, Schuit F., Garcia-Cuenca R., Vandewalle B., Kerr-Conte J., Van Lommel L., Grunwald D., Favier A., Seve M. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J. Cell Sci. 2006; 119: 4199-206. https://doi.org/10.1242/jcs.03164</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Pearson E.R., Donnelly L.A., Kimber C., Whitley A., Doney A., McCarthy V, Hattersley A., Morris A., Palmer C. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007; 56 (8): 2178-82. https://doi.org/10.2337/db07-0440.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Lindi V., Uusitupa M., Lindström J., Louheranta A., Eriksson J., Valle T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Tuomilehto J. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3$year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study Diabetes. 2002; 51 (8): 2581-6. https://doi.org/10.2337/diabetes.51.8.2581.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Salonen J., Uimari P., Aalto J. et al. Type 2 diabetes whole genome association study in four populations: the DiaGen consortium. Am. J. Hum. Genet. 2007; 81 (2): 338-45. https://doi.org/10.1086/520599</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Freathy R., Timpson N., Lawlor D. et al.Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes. 2008; 57 (5): 1419-26. http://dx.doi.org/10.2337/db07-1466.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Копылов В.Ю., Белова М.А. Степень нарушения липидного обмена и состояния эпителия проксимальных почечных канальцев у лиц с ожирением и пациентов с сахарным диабетом 2 типа. Успехи современной науки и образования. 2016; 11 (6): 30-3.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Loder M.K., da Silva Xavier G., McDonald A, Rutter A. TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta-cells. Biochem Soc Trans. 2008; 36 (3): 357-9. https://doi.org/10.1042/BST0360357.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Zhou D., Zhang D., Liu Y, Zhao T., Chen Z., Liu Z., Yu L., Zhang Z., Xu H., He L. The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population. J. Hum Genet. 2009; 54 (7): 433-5. https://doi.org/10.1038/jhg.2009.54.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sakamoto Y., Inoue H., Keshavarz P., Miyawaki K., Yamaguchi Y, Moritani M., Kunika K., Nakamura N., Yoshikawa T., Yasui N., Shiota H., Tanahashi T, Itakura M. SNPs in the KCNJ11-ABCC8 gene locus are associated with type 2 diabetes and blood pressure levels in the Japanese population. J. Hum Genet. 2007; 52 (10): 781-93. https://doi.org/10.1007/s10038-007-0190-x</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Koo B.K., Cho YM., Park B.L., Cheong H.S., Shin H.D., Jang H.C., Kim S.Y, Lee H.K., Park K.S. Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with Type 2 diabetes and hypertension in the Korean population. Diabet Med. 2007; 24: 178-86. https://doi.org/10.1111/j.1464-5491.2006.02050.x.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Gloyn A.L., Weedon M.N., Owen K.R., Turner M.J., Knight B.A., Hitman G., Walker M., Levy J.C., Sampson M., Halford S., McCarthy M.I., Hattersley A.T., Frayling T.M. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003; 52: 568-72. https://doi.org/10.2337/diabe-tes.52.2.568</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Исакова Ж.Т., Кипень В.Н., Талайбекова Э.Т, Айтбаев К.А., Алдашева Н.М., Талайбекова Э.Т, Мукеева С.Б., Осмонкул К.М., Бейшеналиева С.Т, Миррахимов Э.М. Роль и взаимодействие полиморфных вариантов аллельных генов KCNJ11, ADIPOQ, ITLN1, LEP, TCF7L2 и PPARG в увлечении риска развития ожирения в Кыргызской Республики. Молекулярная медицина. 2021; 20 (1): 44-56. https://doi.org/10.25557/2073-7998.2021.01.44-56.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Vaccaro O., Lapice E., Monticelli A., Giacchetti M., Castaldo I., Galasso R., Pinelli M. Donnarumma G., Rivellese A., Cocozza S., Riccardi G. Pro12Ala polymorphism of the PPARgamma2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients. Diabetes Care. 2007; 30 (5): 1156-61. DOI: 10.2337/dc06-1153</mixed-citation></ref></ref-list></back></article>
